133486-61-0Relevant academic research and scientific papers
Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors
Asaki, Tetsuo,Sugiyama, Yukiteru,Hamamoto, Taisuke,Higashioka, Masaya,Umehara, Masato,Naito, Haruna,Niwa, Tomoko
, p. 1421 - 1425 (2007/10/03)
A series of 3-substituted benzamide derivatives structurally related to STI-571 (imatinib mesylate), a Bcr-Abl tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML), was prepared and evaluated for antiproliferative activity against the Bc
Sulfonamide compounds and medicinal use thereof
-
Page column 141, (2010/02/04)
A sulfonamide compound of the formula (I):R 1 --SO 2 NHCO--A--R 2 (I)wherein R 1 is alkyl, alkenyl, alkynyl and the like; A is an optionally substituted heteropolycyclic group except benzimidazolyl, indolyl, 4,7-dihydrobenzimidazolyl and 2,3-dihydrobenzoxazinyl; X is alkylene, oxa, oxa(lower)alkylene and the like; and R 2 is optionally substituted aryl, substituted biphenylyl and the like, a salt thereof and a pharmaceutical composition comprising the same. The sulfonamide compound is effective for the diseases treatable based on their blood sugar level-depressing activity, cGMP-PDE (especially PDE-V)-inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity, smooth muscle cell suppressing activity, and antiallergic activity.
